Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.6952W HIGH $9.82
Volume
120.50 K
Value Traded
454.43 K
Short % Float
3.35%
-18.9%Week
-57.22%1 Month
-65.96%3 Month
-98.92%6 Month
-91.17%5 Year
-91.17%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.21 M
EPS (TTM)
-0.88
P/E Ratio
-
Ent. Value
-2.37 M
Total Shares
2.37 M
Float Shares
1.58 M
Insiders
33.38%
Institutions
4.13%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
LABT Catalyst Timeline
Dated clinical, regulatory and corporate events for Lakewood-Amedex Biotherapeutics Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lakewood-Amedex Biotherapeutics Inc.
26Total events
7Upcoming
1Tier-1 (high impact)
2026 to 2027Coverage
Upcoming catalysts 2
Event history 13
▲PK PD DataNu-3Clinical Data
Positive MIC data for Nu-3 against recent clinical isolates from infected diabetic foot ulcers
infected diabetic foot ulcerssource ↗
▲First Patient DosedNu-3Trial
First patient dosed in Phase 2a trial of Nu-3 for infected diabetic foot ulcers
mildly infected diabetic foot ulcers (iDFU)source ↗
◆Corporate ApprovalCorporate
Annual meeting to vote on increasing authorized common shares and authorizing reverse split
▲Ethics Committee ApprovalNu-3Trial
Central and all site IRB approvals obtained for Phase 2a trial of Nu-3 in iDFU
mildly infected diabetic foot ulcers (iDFU)source ↗
▲Trial InitiationNu-3Trial
Clinical trial site readiness confirmed to commence Phase 2a trial of Nu-3 in iDFU
mildly infected diabetic foot ulcers (iDFU)source ↗
●Trial RegisteredTrial
Registration statement filed covering shares underlying Series C preferred
▲Preclinical PoCNu-3Preclinical
Nu-3 resistance data announced: does not induce resistance in serial passage experiment
infected diabetic foot ulcers (iDFU)source ↗
▲Preclinical PoCNu-3Preclinical
Preclinical safety data supporting dose selection for Phase 2a
infected diabetic foot ulcerssource ↗
◆Oral PresentationNu-3Presentation
PACCARB public meeting discussion on Nu-3 resistance data
infected diabetic foot ulcers (iDFU)source ↗
●Oral PresentationPresentation
PACCARB 27th Public Meeting convened with discussion on National Action Plan
▲Equity OfferingCorporate
Completion of $7.5 million private placement of Series C Convertible Preferred Stock
Past FDA Catalysts and PDUFA Decisions
How LABT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D23 / 100
Pipeline Score
$1M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.5x
rNPV / MCap
Top 88%
Micro Cap(rank 579 of 658)
Percentile Rank
Lakewood-Amedex Biotherapeutics Inc. faces pipeline headwinds (23/100), with $159M risk-adjusted pipeline value, led by Nu-3 in Diabetic Foot Infection (Phase 2), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nu-3 Small moleculeNCT06020235 | Diabetic Foot Infection | Phase 2 | NOT YET_RECRUITING | 60 | Aug 1, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every LABT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Nu-3 | infected diabetic foot ulcers | Phase 2a | 2026-09-28 | MIC values were 2-8 times lower than the planned doses for clinical trials.Read More | Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot UlcersRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LABT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in LABT for Q2 2026. | ||||
LABT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LABT ranks across every disease it competes in
Competitive Position is a premium feature
See how LABT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLABT News
LABT▼ -2.9%today
Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences
Lakewood-Amedex Biotherapeutics announced that CEO Kelvin Cooper will participate in three upcoming conferences, including the Maxim Growth Summit and the ThinkEquity Conference in New York City, and present at IDWeek in Washington D.C. These events aim to showcase the company's Bisphosphocin® antimicrobial technology and engage with key stakeholders in the biotechnology and infectious disease sectors.
Read more →LABT▼ -31.1%on this news· ran to -44% by day 3shared move
Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics announced positive Minimum Inhibitory Concentration (MIC) data for its lead candidate Nu-3, aimed at treating infected diabetic foot ulcers. The data showed effective bactericidal activity against resistant pathogens and supports the ongoing Phase 2a clinical trial. Results indicate a favorable therapeutic window, with topline data expected in early 2027.
Read more →LABTLakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics has initiated patient dosing in its Phase 2a clinical trial for Nu-3, targeting mildly infected diabetic foot ulcers. This milestone is crucial for evaluating the safety and efficacy of Nu-3, a topical antimicrobial gel. Results are anticipated in the first quarter of 2027, potentially advancing treatment options for this challenging condition.
Read more →LABTLakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3
Lakewood-Amedex Biotherapeutics has made significant strides, including its Nasdaq listing under LABT and a $7.5 million funding boost. The company is preparing for a Phase 2a trial of Nu-3 Gel for infected diabetic foot ulcers, supported by positive preclinical data. The appointment of a leading expert as Study Chair enhances the program's credibility.
Read more →LABT▲ +7%on this newsshared move
Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics has received IRB approval and confirmed clinical site readiness to start its Phase 2a trial for Nu-3, aimed at treating mildly infected diabetic foot ulcers. This trial builds on positive preclinical data indicating Nu-3's potential for improved antimicrobial response and wound healing. The company aims to address the urgent need for new treatments for drug-resistant infections.
Read more →LABT▲ +16%on this news
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
Lakewood-Amedex Biotherapeutics Inc. will present at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. CEO Kelvin Cooper will showcase the company's innovative Bisphosphocin® class of antimicrobials aimed at treating infectious diseases. The presentation will include discussions on business strategies and clinical development milestones.
Read more →LABT▲ +83.3%on this news
Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria
Lakewood-Amedex Biotherapeutics has highlighted the resistance data for its candidate Nu-3, aimed at treating infected diabetic foot ulcers. The data aligns with the Presidential Advisory Council's National Action Plan on Combating Antibiotic Resistant Bacteria. Nu-3 demonstrates a unique mechanism of action and a high barrier to resistance, positioning it as a promising option for patients affected by antibiotic-resistant infections.
Read more →LABTLakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel
Lakewood-Amedex Biotherapeutics announced promising preclinical safety data for its Nu-3 gel, aimed at treating infected diabetic foot ulcers. The data supports the selection of doses for an upcoming Phase 2a trial, showing that Nu-3 was well-tolerated and did not inhibit wound healing. The company is preparing to initiate the trial with selected concentrations of the gel.
Read more →LABT▼ -12.8%on this news
Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance
Lakewood-Amedex Biotherapeutics has expressed support for the reintroduction of the PASTEUR Act, aimed at combating antimicrobial resistance (AMR). The company highlights its Bisphosphocin® platform and lead candidate Nu-3, which targets infected diabetic foot ulcers. This initiative is crucial as AMR poses a significant threat to global healthcare.
Read more →LABT▼ -7.8%on this news
Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics has appointed Dr. David G. Armstrong as Study Chair for its Phase 2a trial of Nu-3, targeting infected diabetic foot ulcers. Dr. Armstrong, a leading expert in diabetic foot care, will also serve as a Scientific Advisor for the iDFU program. The trial will assess the safety and efficacy of three concentrations of Nu-3 gel, aiming to fill a critical gap in treatment options for this patient population.
Read more →LABT▼ -5.5%on this newsshared move
Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial Infections
Lakewood-Amedex Biotherapeutics has secured a new patent in Australia for its Bisphosphocin® compounds aimed at treating various antimicrobial infections. This patent adds to the company's extensive intellectual property portfolio, which includes 72 granted patents globally. The CEO emphasized the importance of these innovations in combating antimicrobial resistance, a significant global health crisis.
Read more →LABTLakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum
Lakewood-Amedex Biotherapeutics Inc. will present at the Life Sciences Virtual Investor Forum on June 25, 2026. CEO Kelvin Cooper will discuss the company's growth strategy and its lead candidate, Nu-3, a topical gel for infected diabetic foot ulcers. The company aims to address a significant patient population with this innovative treatment as it moves into Phase 2 clinical trials.
Read more →LABTLakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics has expanded its global intellectual property portfolio by issuing two new patents for its lead candidate, Nu-3, aimed at treating mildly infected diabetic foot ulcers. The company now holds 71 granted patents and 28 pending applications, enhancing its competitive stance in the antimicrobial market. The gel formulation of Nu-3 is set to enter Phase 2 clinical trials.
Read more →LABT▼ -36.7%on this news· ran to -49% by day 3
Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics has announced positive data for its lead candidate, Nu-3, which is advancing towards a Phase 2 clinical trial for treating mildly infected diabetic foot ulcers. The company has successfully completed key formulation and manufacturing processes, demonstrating stability and effectiveness against antibiotic-resistant bacteria. The planned Phase 2 trial aims to further assess the safety and efficacy of Nu-3.
Read more →LABT▲ +6.3%on this news
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors Appointment strengthens Board with seasoned public company biotech executive following recent Nasdaq direct listing
Lakewood-Amedex Biotherapeutics has appointed Dr. Joseph Tucker to its Board of Directors, following its recent direct listing on Nasdaq. Dr. Tucker, a veteran biotech executive, brings over two decades of experience which is expected to strengthen the company’s governance and strategic capabilities. His insights are anticipated to be valuable as Lakewood-Amedex focuses on advancing its growth strategy and developing its lead product, Nu-3, aimed at treating diabetic foot ulcers amid concerns of antibiotic resistance.
Read more →About Lakewood-Amedex Biotherapeutics Inc.
Headquarters8031 COOPER CREEK BLVD., UNIVERSITY PARK, FL, 34201
Founded2006
BIOPHARMAWATCH ELITE PLUS
Trade the next LABT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime